What to expect in the NewAmsterdam Pharma Co N.V. interview process

Based on publicly available sources, NewAmsterdam Pharma Co. N.V. is a late-stage clinical biopharmaceutical company founded in 2019 that focuses on developing oral small molecule therapies for cardiovascular and other metabolic diseases. Headquartered in Aventura, Florida, with a presence in Naarden, Netherlands, the company also maintains a distributed workforce spanning the United States, Netherlands, Switzerland, and the United Kingdom.

Public records indicate that the organization operates on a lean operational model characteristic of a growing clinical-stage biotech. Employee counts place the company between 51 and 250 personnel, with a reported headcount of around 86 employees reflecting notable year-over-year growth of roughly 29.6%. Functionally, the business relies on specialized external collaborations—such as manufacturing partnerships with Piramal for its oral CETP inhibitor, obicetrapib—which shapes a cross-functional work environment where internal teams coordinate closely with external contract development and manufacturing organizations (CDMOs), clinical data partners, and logistics providers.

Financial and corporate records show that the company completed an IPO in 2022 and has raised approximately $377.6M across funding rounds, including a $196M Series A in January 2021 and a $181.6M round in May 2023. Executive appointments extending into mid-2026 highlight ongoing scaling in pipeline marketing and global marketing functions. While specific internal day-to-day cultural metrics, interview procedures, and internal office policies are not detailed in public regulatory and corporate filings, prospective employees can expect a fast-paced environment typical of a publicly traded, clinical-stage biopharmaceutical firm advancing late-stage assets toward commercial readiness.